Contrary to HIF-1α which is a ccRCC suppressor, HIF-2α is a ccRCC oncoprotein and therefore an interesting therapeutic target already evaluated in several phase 2 that showed anti-tumour activity [25,26]. Here, EPAS1 is linked to neoplasm.